Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial.

IF 2.6
Shumin Wang, Meiyi Zhang, Leilei Yu, Fengwei Tian, Wenwei Lu, Gang Wang, Wei Chen, Jialin Wang, Qixiao Zhai
{"title":"Evaluation of the Potential Protective Effects of <i>Lactobacillus</i> Strains against <i>Helicobacter pylori</i> Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial.","authors":"Shumin Wang,&nbsp;Meiyi Zhang,&nbsp;Leilei Yu,&nbsp;Fengwei Tian,&nbsp;Wenwei Lu,&nbsp;Gang Wang,&nbsp;Wei Chen,&nbsp;Jialin Wang,&nbsp;Qixiao Zhai","doi":"10.1155/2022/6432750","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The beneficial effects of probiotic supplementation standard antibiotic therapies for <i>Helicobacter pylori</i> infection have been verified, but the ability of probiotic monotherapy to eradicate <i>H. pylori</i> remains unclear.</p><p><strong>Aim: </strong>To evaluate the accuracy and efficacy of specific <i>Lactobacillus</i> strains against <i>H. pylori</i> infection.</p><p><strong>Methods: </strong>Seventy-eight patients with <i>H. pylori</i> infection were treated with strain <i>L. crispatus</i> G14-5M (<i>L. crispatus</i> CCFM1118) or <i>L. helveticus</i> M2-09-R02-S146 (<i>L. helveticus</i> CCFM1121) or <i>L. plantarum</i> CCFM8610 at a dose of 2 g twice daily for one month. <sup>14</sup>C-urea breath test, the gastrointestinal symptom rating scale, serum pepsinogen concentrations, and serum cytokine concentrations of patients were measured at baseline and end-of-trial to analyze the effect of the <i>Lactobacillus</i> strains in eradicating <i>H. pylori</i> infection and reducing gastrointestinal discomfort in patients. In addition, the composition and abundance of the intestinal microbiota of patients were also measured at end-of-trial.</p><p><strong>Results: </strong>The <sup>14</sup>C-urea breath test value of the three <i>Lactobacillus</i> treatment groups had decreased significantly, and the eradication rate of <i>H. pylori</i> had increased by the end of the trial. In particular, the eradication rate in the G14-5M treatment group was significantly higher than the placebo group (70.59% vs. 15.38%, <i>P</i>=0.0039), indicating that one-month administration of the G14-5M regimen was sufficient to eradicate <i>H. pylori</i> infection. The ingestion of <i>Lactobacillus</i> strains also ameliorated the gastrointestinal symptom rating scale scores, and the serum interleukin-8 concentrations of <i>H. pylori</i>-infected patients appeared to modulate the gut microbiota of patients. However, none of the <i>Lactobacillus</i> strains had a significant effect on general blood physiological characteristics, serum tumor necrosis factor <i>α</i> concentrations, or serum pepsinogen concentrations in the patients.</p><p><strong>Conclusion: </strong>Three <i>Lactobacillus</i> strains significantly alleviate the gastrointestinal discomfort and the gastric inflammatory response of <i>H. pylori</i>-infected patients. The activity of probiotics in eradicating <i>H. pylori</i>infection may be species/strain specific.</p>","PeriodicalId":520793,"journal":{"name":"The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale","volume":" ","pages":"6432750"},"PeriodicalIF":2.6000,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525740/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/6432750","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Background: The beneficial effects of probiotic supplementation standard antibiotic therapies for Helicobacter pylori infection have been verified, but the ability of probiotic monotherapy to eradicate H. pylori remains unclear.

Aim: To evaluate the accuracy and efficacy of specific Lactobacillus strains against H. pylori infection.

Methods: Seventy-eight patients with H. pylori infection were treated with strain L. crispatus G14-5M (L. crispatus CCFM1118) or L. helveticus M2-09-R02-S146 (L. helveticus CCFM1121) or L. plantarum CCFM8610 at a dose of 2 g twice daily for one month. 14C-urea breath test, the gastrointestinal symptom rating scale, serum pepsinogen concentrations, and serum cytokine concentrations of patients were measured at baseline and end-of-trial to analyze the effect of the Lactobacillus strains in eradicating H. pylori infection and reducing gastrointestinal discomfort in patients. In addition, the composition and abundance of the intestinal microbiota of patients were also measured at end-of-trial.

Results: The 14C-urea breath test value of the three Lactobacillus treatment groups had decreased significantly, and the eradication rate of H. pylori had increased by the end of the trial. In particular, the eradication rate in the G14-5M treatment group was significantly higher than the placebo group (70.59% vs. 15.38%, P=0.0039), indicating that one-month administration of the G14-5M regimen was sufficient to eradicate H. pylori infection. The ingestion of Lactobacillus strains also ameliorated the gastrointestinal symptom rating scale scores, and the serum interleukin-8 concentrations of H. pylori-infected patients appeared to modulate the gut microbiota of patients. However, none of the Lactobacillus strains had a significant effect on general blood physiological characteristics, serum tumor necrosis factor α concentrations, or serum pepsinogen concentrations in the patients.

Conclusion: Three Lactobacillus strains significantly alleviate the gastrointestinal discomfort and the gastric inflammatory response of H. pylori-infected patients. The activity of probiotics in eradicating H. pyloriinfection may be species/strain specific.

Abstract Image

Abstract Image

Abstract Image

评价乳酸菌菌株对幽门螺杆菌感染的潜在保护作用:一项随机、双盲、安慰剂对照试验。
背景:益生菌补充标准抗生素治疗幽门螺杆菌感染的有益效果已得到证实,但益生菌单药治疗根除幽门螺杆菌的能力尚不清楚。目的:评价特异性乳酸菌对幽门螺杆菌感染的准确性和疗效。方法:78例幽门螺杆菌感染患者分别用菌株L. crispatus G14-5M (L. crispatus CCFM1118)或L. helveticus M2-09-R02-S146 (L. helveticus CCFM1121)或L. plantarum CCFM8610治疗,剂量为2g,每日2次,疗程1个月。在基线和试验结束时测定患者的14c -尿素呼气试验、胃肠道症状评定量表、血清胃蛋白酶原浓度和血清细胞因子浓度,分析乳杆菌菌株对根除幽门螺杆菌感染和减轻患者胃肠道不适的作用。此外,在试验结束时也测量了患者肠道微生物群的组成和丰度。结果:试验结束时,3个乳杆菌处理组的14c -尿素呼气试验值明显降低,幽门螺杆菌根除率提高。特别是,G14-5M治疗组的根除率显著高于安慰剂组(70.59% vs. 15.38%, P=0.0039),说明G14-5M方案给予1个月的治疗足以根除幽门螺杆菌感染。乳酸菌菌株的摄入也改善了胃肠道症状评分量表得分,幽门螺杆菌感染患者的血清白细胞介素-8浓度似乎可以调节患者的肠道微生物群。然而,没有一种乳酸菌菌株对患者的一般血液生理特征、血清肿瘤坏死因子α浓度或血清胃蛋白酶原浓度有显著影响。结论:3株乳酸菌可显著缓解幽门螺旋杆菌感染患者的胃肠道不适和胃炎症反应。益生菌在根除幽门螺杆菌感染中的活性可能是种/菌株特异性的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信